The Archer® FusionPlex® Myeloid Kit is a targeted next-generation sequencing assay to detect and identify fusions, point mutations and expression levels from 84 genes associated with myeloid-origin malignancies. Using Archer’s proprietary Anchored Multiplex PCR (AMP™)-based enrichment, fusions of all genes in this kit can be identified in a single sequencing assay, even without prior knowledge of fusion partners or breakpoints. Additionally, select genes are targeted for molecular barcode-enabled relative expression level detection and point mutation coverage.
For Research Use Only. Not for use in diagnostic procedures.
# of GSP2s
Input nucleic acid required*
Recommended # of reads
Unique molecular on-target %
Blood, fresh frozen, FFPE
*Input recommendations for FFPE samples vary depending on Archer Preseq® RNA QC score; 50ng input recommended in absence of PreSeq screening
Need to modify your panel?
Add any of our wet lab-validated designs to this panel with Archer Assay Designer to build an assay that fits your exact requirements.
While break-apart FISH can detect both known and novel fusions, sequence information is not obtained and thus FISH cannot identify fusion partner genes nor can it detect other mutations, such as resistance mutations, within fusion genes. Single, unidirectional gene-specific primers (GSPs) used for AMP enable open-ended amplification of fusion genes, identifying fusion breakpoints and partners genes at nucleotide resolution. For example, AMP enabled NGS-based detection of a KMT2A-MLLT3 fusion from reads originating from KMT2A GSPs. Here, these unidirectional KMT2A GSPs enabled amplification and sequencing through the fusion breakpoint between exon 9 of KMT2A and exon 11 of MLLT3, and extended 6 exons into MLLT3.
What translocation is this?
2477 55th Street, Suite 202
Boulder, CO 80301